BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

[News]

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

More... (http://www.news-medical.net/news/20091218/BioMS-Medical-invests-in-Spectral-Diagnostics-to-advance-treatment-for-sepsis.aspx)